Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 306

1.

MR imaging in patients with suspected liver metastases: value of liver-specific contrast agent gadoxetic acid.

Lee KH, Lee JM, Park JH, Kim JH, Park HS, Yu MH, Yoon JH, Han JK, Choi BI.

Korean J Radiol. 2013 Nov-Dec;14(6):894-904. doi: 10.3348/kjr.2013.14.6.894. Epub 2013 Nov 5.

2.
3.
4.

Small (≤1-cm) hepatocellular carcinoma: diagnostic performance and imaging features at gadoxetic acid-enhanced MR imaging.

Yu MH, Kim JH, Yoon JH, Kim HC, Chung JW, Han JK, Choi BI.

Radiology. 2014 Jun;271(3):748-60. doi: 10.1148/radiol.14131996. Epub 2014 Feb 1.

PMID:
24588677
5.

Added value of gadoxetic acid-enhanced hepatobiliary phase MR imaging in the diagnosis of hepatocellular carcinoma.

Ahn SS, Kim MJ, Lim JS, Hong HS, Chung YE, Choi JY.

Radiology. 2010 May;255(2):459-66. doi: 10.1148/radiol.10091388.

PMID:
20413759
6.

Diagnostic accuracy and sensitivity of diffusion-weighted and of gadoxetic acid-enhanced 3-T MR imaging alone or in combination in the detection of small liver metastasis (≤ 1.5 cm in diameter).

Kim YK, Lee MW, Lee WJ, Kim SH, Rhim H, Lim JH, Choi D, Kim YS, Jang KM, Lee SJ, Lim HK.

Invest Radiol. 2012 Mar;47(3):159-66. doi: 10.1097/RLI.0b013e31823a1495.

PMID:
22330426
7.

Additional value of gadoxetic acid-DTPA-enhanced hepatobiliary phase MR imaging in the diagnosis of early-stage hepatocellular carcinoma: comparison with dynamic triple-phase multidetector CT imaging.

Haradome H, Grazioli L, Tinti R, Morone M, Motosugi U, Sano K, Ichikawa T, Kwee TC, Colagrande S.

J Magn Reson Imaging. 2011 Jul;34(1):69-78. doi: 10.1002/jmri.22588. Epub 2011 May 19.

PMID:
21598343
8.

Gadoxetic acid-enhanced magnetic resonance imaging for differentiating small hepatocellular carcinomas (< or =2 cm in diameter) from arterial enhancing pseudolesions: special emphasis on hepatobiliary phase imaging.

Sun HY, Lee JM, Shin CI, Lee DH, Moon SK, Kim KW, Han JK, Choi BI.

Invest Radiol. 2010 Feb;45(2):96-103. doi: 10.1097/RLI.0b013e3181c5faf7.

PMID:
20057319
9.

Hepatocellular carcinoma in patients with chronic liver disease: a comparison of gadoxetic acid-enhanced MRI and multiphasic MDCT.

Baek CK, Choi JY, Kim KA, Park MS, Lim JS, Chung YE, Kim MJ, Kim KW.

Clin Radiol. 2012 Feb;67(2):148-56. doi: 10.1016/j.crad.2011.08.011. Epub 2011 Sep 13.

PMID:
21920517
10.
11.

Added value of hepatobiliary phase gadoxetic acid-enhanced MRI for diagnosing hepatocellular carcinoma in high-risk patients.

Phongkitkarun S, Limsamutpetch K, Tannaphai P, Jatchavala J.

World J Gastroenterol. 2013 Dec 7;19(45):8357-65. doi: 10.3748/wjg.v19.i45.8357.

12.

Small hepatocellular carcinomas: improved sensitivity by combining gadoxetic acid-enhanced and diffusion-weighted MR imaging patterns.

Park MJ, Kim YK, Lee MW, Lee WJ, Kim YS, Kim SH, Choi D, Rhim H.

Radiology. 2012 Sep;264(3):761-70. doi: 10.1148/radiol.12112517. Epub 2012 Jul 27.

PMID:
22843769
13.

Gadoxetic acid-enhanced 3.0 T MR imaging versus multidetector-row CT in the detection of colorectal metastases in fatty liver using intraoperative ultrasound and histopathology as a standard of reference.

Berger-Kulemann V, Schima W, Baroud S, Koelblinger C, Kaczirek K, Gruenberger T, Schindl M, Maresch J, Weber M, Ba-Ssalamah A.

Eur J Surg Oncol. 2012 Aug;38(8):670-6. doi: 10.1016/j.ejso.2012.05.004. Epub 2012 May 30.

PMID:
22652037
14.

Performance of gadoxetic acid-enhanced MRI for detecting hepatocellular carcinoma in recipients of living-related-liver-transplantation: comparison with dynamic multidetector row computed tomography and angiography-assisted computed tomography.

Kakihara D, Nishie A, Harada N, Shirabe K, Tajima T, Asayama Y, Ishigami K, Nakayama T, Takayama Y, Okamoto D, Fujita N, Kishimoto J, Honda H.

J Magn Reson Imaging. 2014 Nov;40(5):1112-20. doi: 10.1002/jmri.24454. Epub 2013 Nov 20.

PMID:
24259437
15.

Detection of liver malignancy with gadoxetic acid-enhanced MRI: is addition of diffusion-weighted MRI beneficial?

Kim YK, Kim CS, Han YM, Lee YH.

Clin Radiol. 2011 Jun;66(6):489-96. doi: 10.1016/j.crad.2010.09.007. Epub 2011 Mar 1. Erratum in: Clin Radiol. 2011 Oct;66(10):1006.

PMID:
21367403
16.

Dynamic enhancement pattern of HCC smaller than 3 cm in diameter on gadoxetic acid-enhanced MRI: comparison with multiphasic MDCT.

Park VY, Choi JY, Chung YE, Kim H, Park MS, Lim JS, Kim KW, Kim MJ.

Liver Int. 2014 Nov;34(10):1593-602. doi: 10.1111/liv.12550. Epub 2014 Apr 10.

PMID:
24673802
17.

Detectability of hepatocellular carcinoma on gadoxetic acid-enhanced MRI at 3 T in patients with severe liver dysfunction: clinical impact of dual-source parallel radiofrequency excitation.

Nishie A, Kakihara D, Asayama Y, Ushijima Y, Takayama Y, Fujita N, Shimamoto D, Shirabe K, Hida T, Honda H.

Clin Radiol. 2015 Mar;70(3):254-61. doi: 10.1016/j.crad.2014.11.006. Epub 2014 Dec 15.

PMID:
25522901
18.

Navigated three-dimensional T1-weighted gradient-echo sequence for gadoxetic acid liver magnetic resonance imaging in patients with limited breath-holding capacity.

Yoon JH, Lee JM, Lee ES, Baek J, Lee S, Iwadate Y, Han JK, Choi BI.

Abdom Imaging. 2015 Feb;40(2):278-88. doi: 10.1007/s00261-014-0214-x.

PMID:
25112454
19.

Detection and classification of different liver lesions: comparison of Gd-EOB-DTPA-enhanced MRI versus multiphasic spiral CT in a clinical single centre investigation.

Böttcher J, Hansch A, Pfeil A, Schmidt P, Malich A, Schneeweiss A, Maurer MH, Streitparth F, Teichgräber UK, Renz DM.

Eur J Radiol. 2013 Nov;82(11):1860-9. doi: 10.1016/j.ejrad.2013.06.013. Epub 2013 Aug 7.

PMID:
23932636
20.

Gadoxetic acid-enhanced MRI versus triple-phase MDCT for the preoperative detection of hepatocellular carcinoma.

Kim SH, Kim SH, Lee J, Kim MJ, Jeon YH, Park Y, Choi D, Lee WJ, Lim HK.

AJR Am J Roentgenol. 2009 Jun;192(6):1675-81. doi: 10.2214/AJR.08.1262.

PMID:
19457834

Supplemental Content

Support Center